Using a method of retroviral gene transduction we have been able to generate conditionally immortalized long-term hematopoietic stem cell lines from primary mouse bone marrow stem cells. Phase I of this project includes testing the same technology in human cells and the subsequent analysis of those cells in the laboratory and in mice. In addition, the project includes knockdown of HIV-1 co-receptors to generate HIV-1 resistant cells in a mouse model. The method to genetically modify the long-term hematopoietic stem cell lines includes state-of-the-art vector transduction with shRNA containing constructs. Phase II of the project will entail testing this approach in a primate model and optimizing large-scale production of genetically-modified conditionally-immortalized long-term hematopoietic stem cells for testing in clinical trials. ? ? This project seeks to refine appropriate methods to genetically manipulate conditionally immortalized hematopoietic stem cell lines to generate HIV-1 resistant cells. Once these methods have been established for the human, the long-term goal to benefit public health will be to use these cells for treating HIV-1 infected patients to re-establish a functional immune system that is protected from endogenous or exogenous sources of HIV. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43HL091740-01
Application #
7419068
Study Section
Special Emphasis Panel (ZRG1-AARR-E (16))
Program Officer
Mitchell, Phyllis
Project Start
2008-09-19
Project End
2010-09-18
Budget Start
2008-09-19
Budget End
2010-09-18
Support Year
1
Fiscal Year
2008
Total Cost
$161,192
Indirect Cost
Name
Taiga Biotechnologies, Inc.
Department
Type
DUNS #
783743938
City
Aurora
State
CO
Country
United States
Zip Code
80045